Abstract:Metabolomics represents an emerging and powerful discipline concerned with the comprehensive analysis of small molecules and provides a powerful approach to discover biomarkers in biological systems. Recent development of biomarkers for diagnosis and therapeutic monitoring of liver-stagnation and spleen-deficiency syndrome (LSS)-type disease remains challenging. This study was undertaken to discover novel potential biomarkers for the non-invasive early diagnosis of human LSS. Urine samples which are potentially a rich source of metabolites were collected from patients with LSS, together with healthy control samples. Metabolite profiling was performed by ultra-performance liquid-chromatography/electrospray-ionization synapt high-definition mass spectrometry (UPLC-Q-TOF-HDMS) in conjunction with multivariate data analysis and ingenuity pathway analysis that were used to select the metabolites to be used for the non-invasive diagnosis of LSS. Twelve urinary differential metabolites contributing to the complete separation of LSS patients from matched healthy controls were identified involving several key metabolic pathways such as pentose and glucuronate interconversions, ascorbate, aldarate, cysteine, methionine, tyrosine, tryptophan, amino sugar and nucleotide sugar metabolism. More importantly, of the 12 differential metabolites, 4 metabolite markers, prolylhydroxyproline, L-homocystine, 2-octenoylcarnitine and α-N-phenylacetyl-L-glutamine, were effective for the diagnosis of human LSS, with an achieved sensitivity of 93.0%. These results demonstrate that robust metabolomics has the potential as a non-invasive strategy and promising screening tool to evaluate the potential of these metabolites in the early diagnosis of LSS patients and provides new insight into pathophysiological mechanisms.

Urine Metabolic Fingerprints Encode Subtypes of Kidney Diseases.

Urine Proteomics Identifies Biomarkers for Diabetic Kidney Disease at Different Stages

Urinary Proteomics As a Novel Tool for Biomarker Discovery in Kidney Diseases

Multi-Parameter Detection of Urine Based on Electropolymerized PANI: PSS/AuNPs/SPCE

Self-Assembled Hyperbranched Gold Nanoarrays Decode Serum United Urine Metabolic Fingerprints for Kidney Tumor Diagnosis.

Urinary Proteome Analysis by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry with Magnetic Beads for Identifying the Pathologic Presentation of Clinical Early Iga Nephropathy

Ultrasensitive and High Reproducible Detection of Urinary Metabolites Using the Tip–Contact Extraction Method Coupled with Negative LDI-MS

Urine and serum metabolic profiling combined with machine learning for autoimmune disease discrimination and classification

Fluorescence Spectroscopic Profiling of Urine Samples for Predicting Kidney Transplant Rejection

Hollow Core-Shell Metal Oxide Heterojunctions for the Urinary Metabolic Fingerprint-Based Noninvasive Diagnostic Strategy.

Machine Learning-Assistant Colorimetric Sensor Arrays for Intelligent and Rapid Diagnosis of Urinary Tract Infection

Rapid and non-invasive renal injury diagnosis unlocked by a glimpse into urinary protein particle size and charge

Accurate Identification of Kidney Injury Progression Via a Fluorescent Biosensor Array

Raspberry-like Polymer@au As Matrix in Mass Spectrometry for Urine Metabolic Fingerprinting

A Multichannel Fluorescent Array Sensor for Discrimination of Different Types of Drug-Induced Kidney Injury

Investigation of Urinary Exosome Metabolic Patterns in Membranous Nephropathy by Titania‐Assisted Intact Exosome Mass Spectrometry

In Vitro Diagnostic Examination and Prognosis Surveillance by Hierarchical Heterojunction-Assisted Metabolic Analysis.

Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach

A Nanosensor for Precise Discrimination of Nephrotoxic Drug Mechanisms Via Dynamic Fluorescence Fingerprint Strategy

Machine learning encodes urine and serum metabolic patterns for autoimmune disease discrimination, classification and metabolic dysregulation analysis